Isolated Vulvar Langerhans Cell Histiocytosis

Clinical Case Study Published in Gynecologic Oncology Reports

Nathalie D. McKenzie, MD
Nnamdi Gwacham, MD
Gynecologic Oncology Program
AdventHealth Cancer Institute

Nnamdi I. Gwacham1, David Ward2, Nathalie D. McKenzie1

1Gynecologic Oncology Program, AdventHealth Cancer Institute, 2Department of Pathology, AdventHealth Orlando, Orlando, FL 32804

Summary
Primary Langerhans cell histiocytosis (LCH) is very rare and is generally encountered more in the childhood and adolescent populations. Its etiology and pathophysiology as well as reliable modes of therapy remain elusive and variable amongst many institutions. It is characterized by proliferation of dendritic cells derived from myeloid precursors. These cells share immunophenotypic and morphologic characteristics with skin Langerhans cells. The disease carries variable presentation and is rarely encountered in the female reproductive tract. When encountered, the vulva is the most common site affected. We report a case of a 31-year-old woman who presented with isolated LCH of the vulva and clitoris that underwent wide local resection and metastatic workup, including robotic-assisted laparoscopic pelvic lymph node dissection and bone marrow biopsy. Metastatic workup was negative, and she remains without recurrence.

Highlights

  • Primary vulvar LCH is rare with less than 40 reported cases.
  • Diagnosis of vulvar LCH requires prompt metastatic workup to rule out multi-system involvement.
  • Treatment protocols for isolated vulvar LCH vary widely, and there is not an established standard of care.
  • Continue surveillance is warranted even after prolonged periods of remission.

For more information or to refer a patient, call GYN Oncology Nurse Navigator Althea Buckner, MSN, APRN-AOCNP, at Call407-303-5909.

Read the Case Study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134974/

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma

AdventHealth Clinical Research Unit (CRU) Executive Director and Medical Director of Genitourinary Oncology Guru Sonpavde, MD, co-authored an article on the AMBASSADOR Phase III clinical trial results...

Read Article about "New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma"
News
AdventHealth Involved in Research to Evaluate First Potential Disease-Modifying Treatment for Epileptic Patients with Dravet Syndrome

Under the leadership of principal investigator Ki Hyeong Lee, MD, MS, medical director of AdventHealth for Children’s pediatric epilepsy center in Orlando, AdventHealth Orlando has been one of two...

Read Article about "AdventHealth Involved in Research to Evaluate First Potential Disease-Modifying Treatment for Epileptic Patients with Dravet Syndrome "
News
AdventHealth for Children Collaborating with n-Lorem Foundation to Provide Personalized Treatments to Patients with Nano-rare Genetic Diseases

The n-Lorem Foundation recently selected AdventHealth for Children in Orlando as one of the first institutions in Florida to collaborate with providing personalized antisense oligonucleotide (ASO)...

Read Article about "AdventHealth for Children Collaborating with n-Lorem Foundation to Provide Personalized Treatments to Patients with Nano-rare Genetic Diseases"
View More Articles